Home Services Products Team Clients Events Contact Vision, Planning, Action
© Copyright 2018 Synerphysics, Inc. All rights reserved. Dillon Capital Strategies is an operating unit of SynerPhysics, Inc.

Joseph S. Dillon, PH.D., MBA

President & CEO

Joseph S. Dillon, Ph.D., MBA, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with nearly 30 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology valuations. Dr. Dillon has screened thousands of opportunities, valued over 400 deals and has been involved in over 40 closed transactions over the course of his career. Since forming Dillon Capital Strategies, Dr. Dillon has consulted dozens of companies, including holding the CEO position at BioPact, a medical nanotechnology company, during its developmental stage. Prior to that, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Metaphysical Sciences, an M.B.A. in International Finance and a bachelors in Finance.

Lainie Mulvanny

Head of Business Development

Lainie Mulvanny earned her BA in Behavioral Science in 2002 at California State Polytechnic University in Pomona, California. Lainie has held business development roles in the pharmaceutical and biotech space, specializing in creating and presenting compelling stories that disrupt current market trends.  She is a launch expert for new products creating success in a goal-driven and innovative way.  Lainie began her career at Ciba Vision, A Novartis company, in San Diego, CA.  Then moving to Arizona in 2004, she partnered with Zila Pharmaceuticals to sell and market an oral cancer screening device.  There she consistently exceeded sales quotas, dominated the Phoenix market, and led the expansion of four more US territories.  Lainie then moved to Merck and Company where she launched multiple new products across several therapeutic areas.  She consistently exceeded national sales objectives earning her several awards and high rankings.  After Merck, Lainie aligned with Sanofi as a Specialty Renal Representative.  Most recently, she was Vice President of Business Development at BioPact, a nano-biotechnology development company, where she spearheaded the BioPact brand, worked closely with the CEO, managed business initiatives, developed company infrastructure, quarterbacked the FDA regulatory process, and presented a novel drug delivery technology to international partners.
Team
© Copyright 2017 Synerphysics, Inc. All rights reserved. Dillon Capital Strategies is an operating unit of Synerphysics.
Site Navigation

Vision, Planning, Action

Joseph S. Dillon, PH.D., MBA

President & CEO

Joseph S. Dillon, Ph.D., MBA, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with nearly 30 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology valuations. Dr. Dillon has screened thousands of opportunities, valued over 400 deals and has been involved in over 40 closed transactions over the course of his career. Since forming Dillon Capital Strategies, Dr. Dillon has consulted dozens of companies, including holding the CEO position at BioPact, a medical nanotechnology company, during its developmental stage. Prior to that, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Metaphysical Sciences, an M.B.A. in International Finance and a bachelors in Finance.

Lainie Mulvanny

Head of Business Development

Lainie Mulvanny earned her BA in Behavioral Science in 2002 at California State Polytechnic University in Pomona, California. Lainie has held business development roles in the pharmaceutical and biotech space, specializing in creating and presenting compelling stories that disrupt current market trends.  She is a launch expert for new products creating success in a goal-driven and innovative way.  Lainie began her career at Ciba Vision, A Novartis company, in San Diego, CA.  Then moving to Arizona in 2004, she partnered with Zila Pharmaceuticals to sell and market an oral cancer screening device.  There she consistently exceeded sales quotas, dominated the Phoenix market, and led the expansion of four more US territories.  Lainie then moved to Merck and Company where she launched multiple new products across several therapeutic areas.  She consistently exceeded national sales objectives earning her several awards and high rankings.  After Merck, Lainie aligned with Sanofi as a Specialty Renal Representative.  Most recently, she was Vice President of Business Development at BioPact, a nano-biotechnology development company, where she spearheaded the BioPact brand, worked closely with the CEO, managed business initiatives, developed company infrastructure, quarterbacked the FDA regulatory process, and presented a novel drug delivery technology to international partners.